2 results
Approved WMOCompleted
To investigate the bleeding pattern and cycle control parameters of the transdermal contraceptive patch (material no. 80876395, FC Patch Low containing 0.55 mg EE and 2.1 mg GSD) in comparison to the EVRA patch (containing 0.6 mg EE and 6 mg NGMN).
Approved WMOCompleted
The primary objective of the study is to evaluate the long-term safety and tolerability of baricitinib in patients who have completed a previous baricitinib RA study. Safety and tolerability assessments will include:* Treatment-emergent adverse…